Microscopic Polyangiitis
Microscopic Polyangiitis Market

Microscopic Polyangiitis

Microscopic Polyangiitis (MPA) is a rare autoimmune condition that causes blood vessel inflammation (vasculitis), restricting blood flow, and lead to organ damage.


Microscopic Polyangiitis Epidemiology Segmentation


  • Total Incident Cases of Microscopic Polyangiitis
  • Gender-specific Microscopic Polyangiitis Incident Cases
  • Age-specific Microscopic Polyangiitis Incident Cases


Microscopic Polyangiitis Epidemiological Insights Observed in 2020


  • The total Microscopic Polyangiitis incident cases were found to be 5,196 in the 7MM countries.
  • In 2020, 660 MPA incident cases were observed in males, whereas 325 MPA incident cases were observed in females in the US.
  • In 2020, 121 MPA incident cases were observed in the age group 0-17 years, whereas 864 MPA incident cases were observed in age group ≥18 years in the US.


Microscopic Polyangiitis Market Insight


The Microscopic Polyangiitis market size was found to be USD 31 million in the 7MM in 2020.


Microscopic Polyangiitis Market Drivers


  • Companies shifting their focus to this area
  • Ubiquitous incidence
  • Increasing approvals by regulatory bodies
  • Rising development of new treatments


Microscopic Polyangiitis Market Barriers


  • Associated side effects with current treatment
  • Limitations associated with the only approved drug
  • Delay in diagnosis due to lacking specific diagnostic procedure


Microscopic Polyangiitis Emerging Drugs


The emerging drugs in the Microscopic Polyangiitis market are


  • Vilobelimab (IFX-1, CaCP290)
  • Vynpenta (Avacopan, CCX168)
  • Belimumab
  • GGS-MPA (Freeze-dried Sulfonated Human Immunoglobulin), and several others


Key Microscopic Polyangiitis Companies


The key companies working in the Microscopic Polyangiitis market are


  • InflaRx GmbH
  • ChemoCentryx
  • Kissei Pharmaceutical
  • Vifor Pharma
  • GlaxoSmithKline
  • Teijin Pharma, and several others